GRIN3B

Summary

GRIN3B (glutamate ionotropic receptor NMDA type subunit 3B, HGNC:16768) is a protein-coding gene on chromosome 19p13.3, encoding Glutamate receptor ionotropic, NMDA 3B (O60391). Component of a non-conventional N-methyl-D-aspartate (NMDA) receptors (NMDARs) that function as heterotetrameric, ligand-gated cation channels with low calcium permeability and low voltage-dependent block by Mg(2+).

The protein encoded by this gene is a subunit of an N-methyl-D-aspartate (NMDA) receptor. The encoded protein is found primarily in motor neurons, where it forms a heterotetramer with GRIN1 to create an excitatory glycine receptor. Variations in this gene have been proposed to be linked to schizophrenia.

Source: NCBI Gene 116444 — RefSeq curated summary.

At a glance

• GWAS associations: 3
• Clinical variants (ClinVar): 274 total
• Druggable target: yes — 22 molecules with ChEMBL bioactivity
• Dosage sensitivity (ClinGen): haploinsufficiency dosage sensitivity unlikely, triplosensitivity no evidence
• MANE Select transcript: NM_138690

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:16768
Approved symbol	GRIN3B
Name	glutamate ionotropic receptor NMDA type subunit 3B
Location	19p13.3
Locus type	gene with protein product
Status	Approved
Aliases	GluN3B
Ensembl gene	ENSG00000116032
Ensembl biotype	protein_coding
OMIM	606651
Entrez	116444

Gene structure

Transcript identifiers

Ensembl transcripts: 2 — 1 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000234389, ENST00000588335

RefSeq mRNA: 1 — MANE Select: NM_138690 NM_138690

CCDS: CCDS32861

Canonical transcript exons

ENST00000234389 — 9 exons

Exon	Start	End
ENSE00000769054	1000419	1000863
ENSE00000769056	1003130	1003722
ENSE00000769058	1004521	1005553
ENSE00000769060	1007628	1007773
ENSE00000769062	1007856	1007971
ENSE00000769063	1008140	1008291
ENSE00000769064	1008618	1008782
ENSE00000769065	1008857	1008927
ENSE00001492453	1009173	1009732

Expression profiles

Bgee: expression breadth ubiquitous, 144 present calls, max score 86.86.

Top tissues by expression

245 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right uterine tube	UBERON:0001302	86.86	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	79.42	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	79.21	silver quality
bronchial epithelial cell	CL:0002328	74.19	gold quality
bronchus	UBERON:0002185	73.26	gold quality
stromal cell of endometrium	CL:0002255	64.15	gold quality
metanephros cortex	UBERON:0010533	64.01	gold quality
right lung	UBERON:0002167	63.57	gold quality
endocervix	UBERON:0000458	63.55	gold quality
granulocyte	CL:0000094	63.12	gold quality
left lobe of thyroid gland	UBERON:0001120	62.89	gold quality
right hemisphere of cerebellum	UBERON:0014890	62.73	gold quality
spleen	UBERON:0002106	62.61	gold quality
adenohypophysis	UBERON:0002196	62.61	gold quality
pituitary gland	UBERON:0000007	62.48	gold quality
tibial nerve	UBERON:0001323	62.47	gold quality
mucosa of paranasal sinus	UBERON:0005030	61.61	gold quality
nasal cavity mucosa	UBERON:0001826	61.46	gold quality
right lobe of thyroid gland	UBERON:0001119	60.94	gold quality
lower esophagus mucosa	UBERON:0035834	60.85	gold quality
left uterine tube	UBERON:0001303	60.53	gold quality
thyroid gland	UBERON:0002046	60.50	gold quality
ganglionic eminence	UBERON:0004023	60.19	gold quality
cerebellar hemisphere	UBERON:0002245	60.16	gold quality
cerebellar cortex	UBERON:0002129	60.03	gold quality
ectocervix	UBERON:0012249	59.63	gold quality
ventricular zone	UBERON:0003053	59.53	gold quality
cerebellum	UBERON:0002037	58.87	gold quality
cortex of kidney	UBERON:0001225	58.68	gold quality
cortical plate	UBERON:0005343	58.33	silver quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	6.52

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

11 targeting GRIN3B, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-4482-3P	99.98	72.50	3147
HSA-LET-7C-3P	99.95	73.42	2862
HSA-MIR-6499-3P	99.90	66.38	1212
HSA-MIR-3177-5P	99.65	70.38	1174
HSA-MIR-6758-3P	99.57	67.55	1078
HSA-MIR-548G-3P	99.48	68.67	2159
HSA-MIR-548AV-3P	99.43	68.50	1721
HSA-MIR-138-2-3P	98.91	68.33	1643
HSA-MIR-6516-5P	98.42	70.19	1551
HSA-MIR-191-3P	83.90	61.25	44

Functional genomics

ClinGen dosage: haploinsufficiency 40 (dosage sensitivity unlikely), triplosensitivity 0 (no evidence). ClinGen Gene Dosage Map

Literature-anchored findings (GeneRIF, showing 8)

• NR3B mRNA expression in the human hippocampal formation (CA1-CA4 and dentate gyrus) and adjacent neocortex may have implications for understanding the role of NMDA receptors for physiological and pathological processes in these forebrain regions. (PMID:15722182)
• cross-talk between NR3B and NR4A receptors is a mechanism modulating the transcriptional activities of these orphan nuclear receptors (PMID:17543277)
• We tested whether genetic dysfunction of GRIN3B is implicated in the pathogenesis of amyotrophic lateral sclerosis (ALS). (PMID:17687115)
• These observations suggest that the genetic variation of the NR3B subunit of the NMDA receptor is not a risk factor for Alzheimer’s dis pathogenesis (PMID:20016182)
• our findings suggest that the over-expression of NR3B subunit of NMDA receptor is a long lasting result of chronic opioid abuse. (PMID:20153313)
• Rs2240158 of GRIN3B was significantly associated with mismatch negativity in healthy subjects. (PMID:24814139)
• Authors investigated the significance of a common human genetic variation of the NMDAR NR3B subunit (PMID:25768306)
• GRIN3B missense mutation is an inherited risk factor for schizophrenia. (PMID:28132660)

Cross-species orthologs

43 orthologs

Organism	Symbol	Gene ID
danio_rerio	grin3ba	ENSDARG00000005364
danio_rerio	grin3bb	ENSDARG00000098667
mus_musculus	Grin3b	ENSMUSG00000035745
rattus_norvegicus	Grin3b	ENSRNOG00000012562
drosophila_melanogaster	GluRIA	FBGN0004619
drosophila_melanogaster	GluRIIA	FBGN0004620
drosophila_melanogaster	GluRIIB	FBGN0020429
drosophila_melanogaster	clumsy	FBGN0026255
drosophila_melanogaster	GluRIID	FBGN0028422
drosophila_melanogaster	Ir7b	FBGN0029965
drosophila_melanogaster	Ir7c	FBGN0029966
drosophila_melanogaster	Ir7g	FBGN0029968
drosophila_melanogaster	Ir25a	FBGN0031634
drosophila_melanogaster	Ir60a	FBGN0034994
drosophila_melanogaster	Ir64a	FBGN0035604
drosophila_melanogaster	Ir68a	FBGN0036150
drosophila_melanogaster	Ir68b	FBGN0036250
drosophila_melanogaster	Ir75a	FBGN0036757
drosophila_melanogaster	Ir75d	FBGN0036829
drosophila_melanogaster	Ir76b	FBGN0036937
drosophila_melanogaster	Ir84a	FBGN0037501
drosophila_melanogaster	Ir85a	FBGN0037630
drosophila_melanogaster	Ir92a	FBGN0038789
drosophila_melanogaster	Grik	FBGN0038840
drosophila_melanogaster	Ekar	FBGN0039916
drosophila_melanogaster	CG11155	FBGN0039927
drosophila_melanogaster	Ir41a	FBGN0040849
drosophila_melanogaster	GluRIIC	FBGN0046113
drosophila_melanogaster	GluRIIE	FBGN0051201
drosophila_melanogaster	Nmdar2	FBGN0053513
drosophila_melanogaster	Ir7e	FBGN0259189
drosophila_melanogaster	Ir94d	FBGN0259193
drosophila_melanogaster	Ir93a	FBGN0259215
drosophila_melanogaster	Ir40a	FBGN0259683
drosophila_melanogaster	Ir76a	FBGN0260874
drosophila_melanogaster	Ir75c	FBGN0261401
drosophila_melanogaster	Ir75b	FBGN0261402
drosophila_melanogaster	GluRIB	FBGN0264000
caenorhabditis_elegans		WBGENE00001612
caenorhabditis_elegans	glr-3	WBGENE00001614
caenorhabditis_elegans		WBGENE00001618
caenorhabditis_elegans		WBGENE00003775
caenorhabditis_elegans		WBGENE00012190

Paralogs (17): GRIN2D (ENSG00000105464), GRIK5 (ENSG00000105737), GRIA2 (ENSG00000120251), GRIA3 (ENSG00000125675), GRIK4 (ENSG00000149403), GRID2 (ENSG00000152208), GRIA4 (ENSG00000152578), GRIA1 (ENSG00000155511), GRIN2C (ENSG00000161509), GRIK3 (ENSG00000163873), GRIK2 (ENSG00000164418), GRIK1 (ENSG00000171189), GRIN1 (ENSG00000176884), GRID1 (ENSG00000182771), GRIN2A (ENSG00000183454), GRIN3A (ENSG00000198785), GRIN2B (ENSG00000273079)

Protein

Protein identifiers

Glutamate receptor ionotropic, NMDA 3B — O60391 (reviewed: O60391)

Alternative names: N-methyl-D-aspartate receptor subtype 3B

All UniProt accessions (1): O60391

UniProt curated annotations — full annotation on UniProt →

Function. Component of a non-conventional N-methyl-D-aspartate (NMDA) receptors (NMDARs) that function as heterotetrameric, ligand-gated cation channels with low calcium permeability and low voltage-dependent block by Mg(2+). Forms glutamatergic receptor complexes with GluN1 and GluN2 subunits which are activated by glycine binding to the GluN1 and GluN3 subunits and L-glutamate binding to GluN2 subunits. Forms excitatory glycinergic receptor complexes with GluN1 alone which are activated by glycine binding to the GluN1 and GluN3 subunits. GluN3B subunit also binds D-serine and, in the absence of glycine, activates glycinergic receptor complexes, but with lower efficacy than glycine. Each GluN3 subunit confers differential attributes to channel properties, including activation, deactivation and desensitization kinetics, pH sensitivity, Ca2(+) permeability, and binding to allosteric modulators.

Subunit / interactions. Forms heterotetrameric channels that contain at least two GluN1 subunits and at least a combination of one GluN2 and one GluN3 subunits (in vitro). Forms heterotetrameric channels composed of two GluN1/zeta subunits (GRIN1), and two identical GluN3 subunits (GRIN3A or GRIN3B) (in vitro). Does not form functional homomeric channels.

Subcellular location. Cell membrane. Postsynaptic cell membrane.

Similarity. Belongs to the glutamate-gated ion channel (TC 1.A.10.1) family. NR3B/GRIN3B subfamily.

RefSeq proteins (1): NP_619635* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001320	Iontro_rcpt_C	Domain
IPR001508	Iono_Glu_rcpt_met	Family
IPR015683	Ionotropic_Glu_rcpt	Family
IPR019594	Glu/Gly-bd	Domain
IPR028082	Peripla_BP_I	Homologous_superfamily

Pfam: PF00060, PF10613

Catalyzed reactions (Rhea), 2 shown:

• Ca(2+)(in) = Ca(2+)(out) (RHEA:29671)
• Na(+)(in) = Na(+)(out) (RHEA:34963)

UniProt features (58 total): sequence variant 26, binding site 10, topological domain 5, glycosylation site 5, region of interest 3, transmembrane region 3, disulfide bond 2, signal peptide 1, chain 1, compositionally biased region 1, intramembrane region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O60391-F1	75.35	0.23

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (10): 531; 533; 533; 538; 538; 701; 701; 702; 745; 745

Disulfide bonds (2): 439–475, 445–476

Glycosylation sites (5): 69, 344, 451, 465, 786

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-9609736	Assembly and cell surface presentation of NMDA receptors

MSigDB gene sets: 117 (showing top): GSE18804_BRAIN_VS_COLON_TUMORAL_MACROPHAGE_DN, GOMF_GLUTAMATE_GATED_RECEPTOR_ACTIVITY, GRAESSMANN_APOPTOSIS_BY_SERUM_DEPRIVATION_UP, GOBP_MONOATOMIC_CATION_TRANSPORT, GOBP_CELL_CELL_SIGNALING, GOBP_REGULATION_OF_SYNAPTIC_PLASTICITY, GOBP_REGULATION_OF_POSTSYNAPTIC_MEMBRANE_POTENTIAL, KEGG_NEUROACTIVE_LIGAND_RECEPTOR_INTERACTION, GOBP_ESTABLISHMENT_OF_PROTEIN_LOCALIZATION_TO_MEMBRANE, GOBP_SYNAPTIC_SIGNALING, GOBP_MEMBRANE_ORGANIZATION, GOBP_SYNAPTIC_TRANSMISSION_GLUTAMATERGIC, REACTOME_TRANSMISSION_ACROSS_CHEMICAL_SYNAPSES, GOBP_LOCALIZATION_WITHIN_MEMBRANE, GOBP_REGULATION_OF_TRANSPORT

GO Biological Process (12): ionotropic glutamate receptor signaling pathway (GO:0035235), synaptic transmission, glutamatergic (GO:0035249), regulation of synaptic plasticity (GO:0048167), modulation of chemical synaptic transmission (GO:0050804), protein insertion into membrane (GO:0051205), regulation of calcium ion transport (GO:0051924), monoatomic cation transmembrane transport (GO:0098655), monoatomic ion transport (GO:0006811), monoatomic ion transmembrane transport (GO:0034220), regulation of postsynaptic membrane potential (GO:0060078), calcium ion transmembrane transport (GO:0070588), regulation of presynaptic membrane potential (GO:0099505)

GO Molecular Function (12): monoatomic cation channel activity (GO:0005261), calcium channel activity (GO:0005262), glutamate receptor activity (GO:0008066), glycine binding (GO:0016594), neurotransmitter receptor activity (GO:0030594), ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potential (GO:0099507), glycine-gated cation channel activity (GO:0160212), transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential (GO:1904315), NMDA glutamate receptor activity (GO:0004972), monoatomic ion channel activity (GO:0005216), ligand-gated monoatomic ion channel activity (GO:0015276), signaling receptor activity (GO:0038023)

GO Cellular Component (10): plasma membrane (GO:0005886), NMDA selective glutamate receptor complex (GO:0017146), presynaptic membrane (GO:0042734), neuronal cell body (GO:0043025), postsynaptic density membrane (GO:0098839), neurotransmitter receptor complex (GO:0098878), membrane (GO:0016020), monoatomic ion channel complex (GO:0034702), synapse (GO:0045202), postsynaptic membrane (GO:0045211)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Activation of NMDA receptors and postsynaptic events	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
glutamate-gated receptor activity	2
chemical synaptic transmission	2
calcium ion transport	2
regulation of membrane potential	2
monoatomic ion channel activity	2
transmitter-gated monoatomic ion channel activity	2
synaptic membrane	2
glutamate receptor signaling pathway	1
ligand-gated ion channel signaling pathway	1
modulation of chemical synaptic transmission	1
regulation of biological quality	1
regulation of trans-synaptic signaling	1
intracellular protein localization	1
membrane organization	1
establishment of protein localization to membrane	1
regulation of metal ion transport	1
monoatomic cation transport	1
monoatomic ion transmembrane transport	1
transport	1
monoatomic ion transport	1
transmembrane transport	1
monoatomic cation transmembrane transport	1
monoatomic cation transmembrane transporter activity	1
monoatomic cation channel activity	1
calcium ion transmembrane transporter activity	1
transmembrane signaling receptor activity	1
glutamate binding	1
amino acid binding	1
carboxylic acid binding	1
cation binding	1
signaling receptor activity	1
ligand-gated monoatomic ion channel activity	1
presynaptic membrane	1
regulation of presynaptic membrane potential	1
ligand-gated monoatomic cation channel activity	1
regulation of postsynaptic membrane potential	1
voltage-gated monoatomic ion channel activity	1
monoatomic ion transmembrane transporter activity	1
channel activity	1
ligand-gated channel activity	1

Protein interactions and networks

STRING

880 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
GRIN3B	GRIN1	P35437	990
GRIN3B	GRIN2D	O15399	988
GRIN3B	GRIN2A	Q12879	988
GRIN3B	GRIN2B	Q13224	985
GRIN3B	GRIN2C	Q14957	985
GRIN3B	GRIN3A	Q8TCU5	981
GRIN3B	KCND2	Q9NZV8	571
GRIN3B	BDNF	P23560	537
GRIN3B	GRM4	Q14833	489
GRIN3B	ESRRG	P62508	480
GRIN3B	CACNG2	Q9Y698	466
GRIN3B	GRM1	Q13255	456
GRIN3B	SLC7A1	P30825	447
GRIN3B	GRM8	O00222	445
GRIN3B	GRM6	O15303	445

IntAct

3 interactions, top by confidence:

A	B	Type	Score
GRIN3B	DAPK3	psi-mi:“MI:0914”(association)	0.350
GRIN3B	TPD52L2	psi-mi:“MI:0914”(association)	0.350

BioGRID (38): GRIN2A (Affinity Capture-Western), GRIN1 (Affinity Capture-Western), GRIN3B (Affinity Capture-Western), GRIN3B (Affinity Capture-Western), GRIN1 (Affinity Capture-Western), C19orf44 (Affinity Capture-MS), TPD52L1 (Affinity Capture-MS), C9orf16 (Affinity Capture-MS), EDEM2 (Affinity Capture-MS), ABCB9 (Affinity Capture-MS), DAPK3 (Affinity Capture-MS), MXRA7 (Affinity Capture-MS), HSPA5 (Affinity Capture-MS), CGRRF1 (Affinity Capture-MS), GRIN3A (Affinity Capture-MS)

ESM2 similar proteins: A6NGC4, A6NKX4, A6NM10, D3YZZ2, O35595, O46547, O60391, O77808, O95528, P30518, P43119, P46092, P46095, P48044, P48748, Q14626, Q3SYU3, Q3ZAV1, Q4U2R8, Q4W8A3, Q5RF19, Q5U419, Q64385, Q684M3, Q6UXD7, Q6UXT9, Q6YNI2, Q863Y8, Q86SM5, Q8CFZ5, Q8IXF9, Q8WUG5, Q91X56, Q924U0, Q96S37, Q99MF4, Q9BGL8, Q9BZ11, Q9H1Z9, Q9H228

Diamond homologs: A0A1L8F5J9, A2AIR5, O15399, O60391, Q8TCU5, Q8VHN2, Q91ZU9, Q9R1M7, A0A2R8QF68, A7XY94, B1AS29, B7ZSK1, O43424, P0AEQ3, P0AEQ4, P0AEQ5, P22756, P35436, P39086, P42264, Q00959, Q00960, Q00961, Q01097, Q01098, Q01812, Q03391, Q10914, Q12879, Q13003, Q13224, Q14957, Q38PU2, Q38PU4, Q5IS45, Q5R1P3, Q60934, Q61625, Q62645, Q63226

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

274 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	248
Likely benign	10
Benign	8

Top pathogenic / likely-pathogenic (0)

SpliceAI

1580 predictions. Top by Δscore:

Variant	Effect	Δscore
19:1000887:G:GT	donor_gain	1.0000
19:1003129:GAACC:G	acceptor_gain	1.0000
19:1005549:CCAAG:C	donor_loss	1.0000
19:1005551:AAGG:A	donor_loss	1.0000
19:1005552:AGGT:A	donor_loss	1.0000
19:1005555:T:A	donor_loss	1.0000
19:1007774:G:GG	donor_gain	1.0000
19:1007851:A:AG	acceptor_gain	1.0000
19:1007852:G:GA	acceptor_gain	1.0000
19:1007852:GCA:G	acceptor_gain	1.0000
19:1007970:GG:G	donor_gain	1.0000
19:1007971:GG:G	donor_gain	1.0000
19:1007972:G:GG	donor_gain	1.0000
19:1008243:GTG:G	donor_gain	1.0000
19:1009171:AGC:A	acceptor_gain	1.0000
19:1009172:GC:G	acceptor_gain	1.0000
19:1009172:GCG:G	acceptor_gain	1.0000
19:1000862:CGGT:C	donor_loss	0.9900
19:1000864:G:GG	donor_gain	0.9900
19:1000865:T:A	donor_loss	0.9900
19:1003124:TCCCA:T	acceptor_loss	0.9900
19:1003127:CA:C	acceptor_loss	0.9900
19:1003128:A:AG	acceptor_gain	0.9900
19:1003129:G:GA	acceptor_gain	0.9900
19:1003129:G:GT	acceptor_loss	0.9900
19:1003129:GA:G	acceptor_gain	0.9900
19:1003129:GAA:G	acceptor_gain	0.9900
19:1003129:GAAC:G	acceptor_gain	0.9900
19:1004794:T:TA	acceptor_gain	0.9900
19:1005554:G:GG	donor_gain	0.9900

AlphaMissense

6604 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
19:1007882:T:C	F742S	0.997
19:1007885:T:A	I743N	0.996
19:1005131:T:C	F544L	0.995
19:1005133:C:A	F544L	0.995
19:1005133:C:G	F544L	0.995
19:1007891:A:T	D745V	0.995
19:1005092:A:C	S531R	0.994
19:1005094:C:A	S531R	0.994
19:1005094:C:G	S531R	0.994
19:1007882:T:G	F742C	0.994
19:1007959:T:C	F768L	0.994
19:1007961:C:A	F768L	0.994
19:1007961:C:G	F768L	0.994
19:1007673:A:C	S700R	0.993
19:1007675:C:A	S700R	0.993
19:1007675:C:G	S700R	0.993
19:1007879:C:A	A741D	0.993
19:1007960:T:G	F768C	0.993
19:1005132:T:C	F544S	0.992
19:1007890:G:C	D745H	0.992
19:1008246:G:C	W807C	0.992
19:1008246:G:T	W807C	0.992
19:1005098:A:C	S533R	0.991
19:1005100:T:A	S533R	0.991
19:1005100:T:G	S533R	0.991
19:1007881:T:C	F742L	0.991
19:1007883:C:A	F742L	0.991
19:1007883:C:G	F742L	0.991
19:1007903:T:C	L749P	0.991
19:1005132:T:G	F544C	0.990

dbSNP variants (sampled 300 via entrez): RS1000013465 (19:998835 AT>A,ATT), RS1000052882 (19:999889 T>A,C), RS1000058557 (19:1007447 T>TA), RS1000101552 (19:1000024 G>A), RS1000127338 (19:999843 C>A,T), RS1000481993 (19:1009991 C>G), RS1001217364 (19:1009352 T>C), RS1001511400 (19:1002021 C>T), RS1001631342 (19:1008692 C>G,T), RS1001656766 (19:1005576 G>A), RS1001761257 (19:999257 C>A,T), RS1001941197 (19:1004968 G>C), RS1002017434 (19:1007624 G>A), RS1002383281 (19:1008833 A>C,G), RS1002688173 (19:1009917 G>A,T)

Disease associations

OMIM: gene MIM:606651 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): neurodevelopmental disorder (MONDO:0700092)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST001963_1	Alzheimer’s disease (late onset)	2.000000e-09
GCST005974_20	Neutrophil count	3.000000e-08
GCST006804_167	Red cell distribution width	2.000000e-09

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0004833	neutrophil count
EFO:0009188	Red cell distribution width

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D065886	Neurodevelopmental Disorders	F03.625

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (2): CHEMBL2094124 (PROTEIN COMPLEX GROUP), CHEMBL6066548 (PROTEIN COMPLEX)

Molecules with ChEMBL bioactivity

22 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 1,350,441 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL52440	DEXTROMETHORPHAN	4	33,223
CHEMBL592	LEVORPHANOL	4	75,131
CHEMBL660	AMANTADINE	4	69,750
CHEMBL71	CHLORPROMAZINE	4	45,827
CHEMBL742	KETAMINE	4	101,983
CHEMBL807	MEMANTINE	4	34,597
CHEMBL86715	PROCYCLIDINE	4	5,456
CHEMBL900	ORPHENADRINE	4	8,087
CHEMBL575060	GLUTAMIC ACID	3	929,756
CHEMBL1254766	DEXTRORPHAN	2	6,521
CHEMBL14935	TEZAMPANEL ANHYDROUS	2	106
CHEMBL17350	TRAXOPRODIL	2	2,547
CHEMBL182066	RADIPRODIL	2	126
CHEMBL22207	RACEMETHORPHAN	2	748
CHEMBL275528	PHENCYCLIDINE	2	25,537
CHEMBL284237	DIZOCILPINE	2	5,015
CHEMBL289832	LICOSTINEL	2	566
CHEMBL334491	BUDIPINE	2	2,513
CHEMBL39664	SELFOTEL	2	2,588
CHEMBL452461	PERZINFOTEL	2	364
CHEMBL467084	LANICEMINE	2
CHEMBL299155	TRANSTORINE	1

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB variants

3 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs2240158	GRIN3B		0.00	0
rs2285906	GRIN3B		0.00	0
rs2285907	GRIN3B		0.00	0

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: lgic — Ionotropic glutamate receptors

ChEMBL bioactivities

439 potent at pChembl≥5 of 567 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
9.30	IC50	0.5	nM	CHEMBL276708
9.10	IC50	0.8	nM	CHEMBL12513
9.02	Ki	0.96	nM	CHEMBL39881
9.00	IC50	1	nM	CHEMBL12804
8.92	IC50	1.2	nM	CHEMBL12242
8.92	Ki	1.2	nM	DIZOCILPINE
8.85	Ki	1.4	nM	CHEMBL5185347
8.82	IC50	1.5	nM	CHEMBL537478
8.82	IC50	1.5	nM	CHEMBL274422
8.82	IC50	1.5	nM	CHEMBL273662
8.77	IC50	1.7	nM	CHEMBL269683
8.71	Ki	1.94	nM	CNS-5161
8.70	IC50	2	nM	CHEMBL536107
8.70	Ki	2	nM	CHEMBL299294
8.64	Ki	2.3	nM	CHEMBL39773
8.59	Ki	2.6	nM	CHEMBL290738
8.59	IC50	2.6	nM	CHEMBL450325
8.52	Ki	3	nM	CHEMBL5208012
8.52	IC50	3	nM	CHEMBL552664
8.52	Ki	3	nM	CHEMBL166935
8.52	Ki	3	nM	CHEMBL166991
8.51	Ki	3.1	nM	CHEMBL290649
8.48	Ki	3.3	nM	CHEMBL5208606
8.47	Ki	3.4	nM	CHEMBL66626
8.46	Ki	3.5	nM	CHEMBL50872
8.42	Ki	3.8	nM	CHEMBL68831
8.42	Ki	3.8	nM	CHEMBL306899
8.40	IC50	4	nM	CHEMBL363010
8.40	IC50	4	nM	BESONPRODIL
8.40	IC50	4	nM	CHEMBL317229
8.40	Ki	4	nM	CHEMBL354482
8.40	Ki	4	nM	CHEMBL170552
8.40	Ki	4	nM	CHEMBL169695
8.39	IC50	4.1	nM	CHEMBL557993
8.36	Ki	4.4	nM	CHEMBL40730
8.36	IC50	4.4	nM	CHEMBL61720
8.35	Ki	4.5	nM	CHEMBL100656
8.33	IC50	4.7	nM	CHEMBL297881
8.31	Ki	4.9	nM	CHEMBL70918
8.30	IC50	5	nM	CHEMBL363722
8.30	Ki	5	nM	CHEMBL166697
8.29	Ki	5.1	nM	CHEMBL38994
8.25	Ki	5.6	nM	CHEMBL305195
8.23	IC50	5.9	nM	LICOSTINEL
8.22	IC50	6	nM	RADIPRODIL
8.22	IC50	6	nM	CHEMBL305195
8.22	Ki	6	nM	CHEMBL305195
8.22	IC50	6	nM	CHEMBL126929
8.18	Ki	6.6	nM	CHEMBL289607
8.17	Ki	6.8	nM	DIZOCILPINE

PubChem BioAssay actives

376 with measured affinity, of 875 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
(2,3-dioxo-1,4-dihydroquinoxalin-5-yl)methylphosphonic acid	144039: Compound was tested in vitro for its inhibitory activity at 1 uM concentration against N-methyl-D-aspartate glutamate receptor by using [3H]CGP-39653 binding assay	ic50	0.0005	uM
[7-(4-chlorophenyl)-2,3-dioxo-1,4-dihydroquinoxalin-5-yl]methylphosphonic acid	144043: In vitro inhibitory activity at 1 uM concentration against N-methyl-D-aspartate glutamate receptor, using [3H]CGP-39653 binding assay	ic50	0.0008	uM
(7-fluoro-2,3-dioxo-1,4-dihydroquinoxalin-5-yl)methylphosphonic acid	144043: In vitro inhibitory activity at 1 uM concentration against N-methyl-D-aspartate glutamate receptor, using [3H]CGP-39653 binding assay	ic50	0.0010	uM
2-[(12S)-7-bromo-2,3-dioxo-1,4-diazatricyclo[7.3.1.05,13]trideca-5,7,9(13)-trien-12-yl]-N-phenylacetamide	1859114: Displacement of [3H]DCKA from NMDA receptor (unknown origin)	ki	0.0010	uM
(1S,9R)-1-methyl-16-azatetracyclo[7.6.1.02,7.010,15]hexadeca-2,4,6,10,12,14-hexaene	156805: The compound was tested for its ability to block PCP N-methyl-D-aspartate glutamate receptor at the PCP (phencyclidine) binding site in postmortem human frontal cortex.	ki	0.0012	uM
[hydroxy-(7-nitro-2,3-dioxo-1,4-dihydroquinoxalin-5-yl)methyl]phosphonic acid	144043: In vitro inhibitory activity at 1 uM concentration against N-methyl-D-aspartate glutamate receptor, using [3H]CGP-39653 binding assay	ic50	0.0012	uM
2-[(11S)-7-bromo-11-ethyl-2,3-dioxo-1,4-diazatricyclo[7.3.1.05,13]trideca-5,7,9(13)-trien-12-yl]acetic acid	1859114: Displacement of [3H]DCKA from NMDA receptor (unknown origin)	ki	0.0014	uM
(7-bromo-2,3-dioxo-1,4-dihydroquinoxalin-5-yl)methylphosphonic acid	144043: In vitro inhibitory activity at 1 uM concentration against N-methyl-D-aspartate glutamate receptor, using [3H]CGP-39653 binding assay	ic50	0.0015	uM
[(2,3-dioxo-1,4-dihydroquinoxalin-5-yl)-hydroxymethyl]phosphonic acid	144043: In vitro inhibitory activity at 1 uM concentration against N-methyl-D-aspartate glutamate receptor, using [3H]CGP-39653 binding assay	ic50	0.0015	uM
[(benzylamino)-(7-nitro-2,3-dioxo-1,4-dihydroquinoxalin-5-yl)methyl]phosphonic acid;hydrobromide	144043: In vitro inhibitory activity at 1 uM concentration against N-methyl-D-aspartate glutamate receptor, using [3H]CGP-39653 binding assay	ic50	0.0015	uM
(7-chloro-2,3-dioxo-1,4-dihydroquinoxalin-5-yl)methylphosphonic acid	144043: In vitro inhibitory activity at 1 uM concentration against N-methyl-D-aspartate glutamate receptor, using [3H]CGP-39653 binding assay	ic50	0.0017	uM
2-(2-chloro-5-methylsulfanylphenyl)-1-methyl-1-(3-methylsulfanylphenyl)guanidine	143453: In vitro displacement of [3H]MK-801 from N-methyl-D-aspartate glutamate receptor	ki	0.0019	uM
[(benzylamino)-(2,3-dioxo-1,4-dihydroquinoxalin-5-yl)methyl]phosphonic acid;hydrobromide	144043: In vitro inhibitory activity at 1 uM concentration against N-methyl-D-aspartate glutamate receptor, using [3H]CGP-39653 binding assay	ic50	0.0020	uM
2-[[2-(3,4-dihydro-1H-isoquinolin-2-yl)-4-pyridinyl]amino]ethanol	143451: Binding affinity against NMDA receptor by displacement of [3H]Ro-256981	ki	0.0020	uM
2-[(12S)-7-bromo-2,3-dioxo-1,4-diazatricyclo[7.3.1.05,13]trideca-5,7,9(13)-trien-12-yl]acetic acid	1859114: Displacement of [3H]DCKA from NMDA receptor (unknown origin)	ki	0.0023	uM
2-(7-bromo-2,3-dioxo-1,4-diazatricyclo[7.3.1.05,13]trideca-5,7,9(13)-trien-12-yl)-N-phenylacetamide	1859114: Displacement of [3H]DCKA from NMDA receptor (unknown origin)	ki	0.0026	uM
6,7-dichloro-5-[1-(1,2,4-triazol-4-yl)propyl]-1,4-dihydroquinoxaline-2,3-dione	1859120: Displacement of [3H]L-689560 from NMDA receptor (unknown origin)	ic50	0.0026	uM
2-[(11S)-7-bromo-11-methyl-2,3-dioxo-1,4-diazatricyclo[7.3.1.05,13]trideca-5,7,9(13)-trien-12-yl]-N-phenylacetamide	1859114: Displacement of [3H]DCKA from NMDA receptor (unknown origin)	ki	0.0030	uM
[(cyclohexylmethylamino)-(7-nitro-2,3-dioxo-1,4-dihydroquinoxalin-5-yl)methyl]phosphonic acid;hydrochloride	144043: In vitro inhibitory activity at 1 uM concentration against N-methyl-D-aspartate glutamate receptor, using [3H]CGP-39653 binding assay	ic50	0.0030	uM
2-(3,4-dihydro-1H-isoquinolin-2-yl)pyridin-4-amine	143451: Binding affinity against NMDA receptor by displacement of [3H]Ro-256981	ki	0.0030	uM
2-(3,4-dihydro-1H-isoquinolin-2-yl)-6-ethylpyridin-4-amine	143451: Binding affinity against NMDA receptor by displacement of [3H]Ro-256981	ki	0.0030	uM
2-[(11S)-7-chloro-11-methyl-2,3-dioxo-1,4-diazatricyclo[7.3.1.05,13]trideca-5,7,9(13)-trien-12-yl]-N-phenylacetamide	1859114: Displacement of [3H]DCKA from NMDA receptor (unknown origin)	ki	0.0031	uM
2-[(11S)-7-bromo-11-methyl-2,3-dioxo-1,4-diazatricyclo[7.3.1.05,13]trideca-5,7,9(13)-trien-12-yl]acetic acid	1859114: Displacement of [3H]DCKA from NMDA receptor (unknown origin)	ki	0.0033	uM
4-[3-(4-benzylpiperidin-1-yl)-2-methylpropyl]phenol	143454: Displacement of [3H]25-6981 from N-methyl-D-aspartate glutamate receptor	ki	0.0034	uM
2-[[2-(3,4-dihydro-1H-isoquinolin-2-yl)quinolin-4-yl]amino]ethanol	143451: Binding affinity against NMDA receptor by displacement of [3H]Ro-256981	ki	0.0035	uM
4-[3-(4-benzylpiperidin-1-yl)-1-hydroxypropyl]phenol	143454: Displacement of [3H]25-6981 from N-methyl-D-aspartate glutamate receptor	ki	0.0038	uM
4-[3-(4-benzylpiperidin-1-yl)-2-hydroxypropyl]phenol	143454: Displacement of [3H]25-6981 from N-methyl-D-aspartate glutamate receptor	ki	0.0038	uM
2-(4-benzylpiperidin-1-yl)-2-oxo-N-(2-oxo-1,3-dihydrobenzimidazol-5-yl)acetamide	241037: Inhibition of [3H]-Ro-25-6981 binding to NMDA receptor	ic50	0.0040	uM
6-[2-[4-[(4-fluorophenyl)methyl]piperidin-1-yl]ethylsulfinyl]-3H-1,3-benzoxazol-2-one	143455: Inhibition of [3H]Ro-256981 binding to N-methyl-D-aspartate glutamate receptor	ic50	0.0040	uM
1-[2-(4-hydroxyphenoxy)ethyl]-4-[(4-methylphenyl)methyl]piperidin-4-ol	241037: Inhibition of [3H]-Ro-25-6981 binding to NMDA receptor	ic50	0.0040	uM
[4-amino-6-(3,4-dihydro-1H-isoquinolin-2-yl)-2-pyridinyl]methanol	143451: Binding affinity against NMDA receptor by displacement of [3H]Ro-256981	ki	0.0040	uM
2-[[2-(3,4-dihydro-1H-isoquinolin-2-yl)-6-methyl-4-pyridinyl]amino]ethanol	143451: Binding affinity against NMDA receptor by displacement of [3H]Ro-256981	ki	0.0040	uM
2-(3,4-dihydro-1H-isoquinolin-2-yl)-5-methylpyridin-4-amine	143451: Binding affinity against NMDA receptor by displacement of [3H]Ro-256981	ki	0.0040	uM
[(furan-2-ylmethylamino)-(7-nitro-2,3-dioxo-1,4-dihydroquinoxalin-5-yl)methyl]phosphonic acid;hydrobromide	144043: In vitro inhibitory activity at 1 uM concentration against N-methyl-D-aspartate glutamate receptor, using [3H]CGP-39653 binding assay	ic50	0.0041	uM
6,7-dichloro-5-[(1-propylimidazol-4-yl)methyl]-1,4-dihydroquinoxaline-2,3-dione	1859120: Displacement of [3H]L-689560 from NMDA receptor (unknown origin)	ic50	0.0044	uM
2-[(11S)-7-chloro-11-methyl-2,3-dioxo-1,4-diazatricyclo[7.3.1.05,13]trideca-5,7,9(13)-trien-12-yl]acetic acid	1859114: Displacement of [3H]DCKA from NMDA receptor (unknown origin)	ki	0.0044	uM
(1S,9R)-10-[(2R)-2-methoxypropyl]-1,13,13-trimethyl-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-trien-5-ol	1960006: Antagonist activity at NMDA receptor (unknown origin) assessed as inhibition constant	ki	0.0045	uM
7-chloro-6-methyl-5-nitro-1,4-dihydroquinoxaline-2,3-dione	143443: Inhibition of [3H]DCKA binding to N-methyl-D-aspartate glutamate receptor	ic50	0.0047	uM
1-[(2R)-2-hydroxy-3-(4-hydroxyphenyl)propyl]-4-[(4-methylphenyl)methyl]piperidin-4-ol	143454: Displacement of [3H]25-6981 from N-methyl-D-aspartate glutamate receptor	ki	0.0049	uM
2-[4-[(4-fluorophenyl)methyl]piperidin-1-yl]-2-oxo-N-(2-oxo-1,3-dihydrobenzimidazol-5-yl)acetamide	241037: Inhibition of [3H]-Ro-25-6981 binding to NMDA receptor	ic50	0.0050	uM
2-(3,4-dihydro-1H-isoquinolin-2-yl)-6-methylpyridin-4-amine	143451: Binding affinity against NMDA receptor by displacement of [3H]Ro-256981	ki	0.0050	uM
2-(7-chloro-2,3-dioxo-1,4-diazatricyclo[7.3.1.05,13]trideca-5,7,9(13)-trien-12-yl)acetic acid	1859114: Displacement of [3H]DCKA from NMDA receptor (unknown origin)	ki	0.0051	uM
4-[(1R,2S)-3-(4-benzylpiperidin-1-yl)-1-hydroxy-2-methylpropyl]phenol	143454: Displacement of [3H]25-6981 from N-methyl-D-aspartate glutamate receptor	ki	0.0056	uM
6,7-dichloro-5-nitro-1,4-dihydroquinoxaline-2,3-dione	143443: Inhibition of [3H]DCKA binding to N-methyl-D-aspartate glutamate receptor	ic50	0.0059	uM
2-[4-[(4-fluorophenyl)methyl]piperidin-1-yl]-2-oxo-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide	241037: Inhibition of [3H]-Ro-25-6981 binding to NMDA receptor	ic50	0.0060	uM
(4-benzylpiperidin-1-yl)-(4,6-dihydroxy-1H-indol-2-yl)methanone	143455: Inhibition of [3H]Ro-256981 binding to N-methyl-D-aspartate glutamate receptor	ic50	0.0060	uM
2-(7-chloro-2,3-dioxo-1,4-diazatricyclo[7.3.1.05,13]trideca-5,7,9(13)-trien-12-yl)-N-phenylacetamide	1859114: Displacement of [3H]DCKA from NMDA receptor (unknown origin)	ki	0.0066	uM
5,6,7-trichloro-4-hydroxy-3-nitroso-1H-quinolin-2-one	143443: Inhibition of [3H]DCKA binding to N-methyl-D-aspartate glutamate receptor	ic50	0.0070	uM
1-[(1S,2S)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]-4-phenylpiperidin-4-ol	241037: Inhibition of [3H]-Ro-25-6981 binding to NMDA receptor	ic50	0.0070	uM
(1R)-1-(4-chlorophenyl)-2-[(1R)-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-1-yl]ethanol	238983: Mean inhibitory constant against porcine N-methyl-D-aspartate (NMDA) glutamate receptor; n=3	ki	0.0070	uM

CTD chemical–gene interactions

24 total (human), top 24 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	decreases expression, increases expression	3
Estradiol	affects expression, affects cotreatment, increases expression	2
triphenyl phosphate	affects expression	1
propionaldehyde	increases expression	1
ferrous chloride	decreases expression	1
nutlin 3	affects cotreatment, increases expression	1
ICG 001	increases expression	1
abrine	decreases expression	1
bisphenol S	decreases expression	1
jinfukang	affects cotreatment, increases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	increases expression	1
Air Pollutants	affects expression, increases abundance	1
Benzo(a)pyrene	increases methylation	1
Camptothecin	increases expression	1
Cisplatin	affects cotreatment, increases expression	1
Dactinomycin	affects cotreatment, increases expression	1
Methotrexate	affects response to substance	1
Oxygen	increases expression	1
Ozone	affects expression, increases abundance	1
Phthalic Acids	increases methylation	1
Rotenone	increases expression	1
Tobacco Smoke Pollution	decreases expression	1
Valproic Acid	increases methylation	1
Aflatoxin B1	increases methylation	1

ChEMBL screening assays

182 unique, capped per target: 170 binding, 7 functional, 4 admet, 1 toxicity

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1247908	Binding	Binding affinity to human recombinant NMDA receptor	Spiroindolones, a potent compound class for the treatment of malaria. — Science
CHEMBL2208698	Functional	Antagonist activity at NMDA receptor (unknwon origin)	Synopsis of some recent tactical application of bioisosteres in drug design. — J Med Chem
CHEMBL4680007	ADMET	Inhibition of NMDA receptor (unknown origin)	Fragment-Based Discovery of Novel Allosteric MEK1 Binders. — ACS Med Chem Lett

Cellosaurus cell lines

1 cell lines: 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D9FU	Ubigene HEK293 GRIN3B KO	Transformed cell line	Female

Clinical trials (associated diseases)

202 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT04586348	PHASE4	UNKNOWN	Prenatal Iodine Supplementation and Early Childhood Neurodevelopment
NCT04873115	PHASE4	UNKNOWN	Double-blind, Placebo-controlled, Randomized Clinical Trial Comparing the Efficacy and Safety of Sialanar Plus orAl rehabiLitation Against Placebo Plus Oral Rehabilitation for chIldren and Adolescents With seVere Sialorrhoea and Neurodisabilties,
NCT02559102	PHASE3	COMPLETED	Dexmedetomidine Sedation Versus General Anaesthesia for Inguinal Hernia Surgery in Infants
NCT02757079	PHASE3	COMPLETED	Study of the Efficacy and Safety of NPC-15 for Sleep Disorders of Children With Neurodevelopmental Disorders
NCT06915480	PHASE3	RECRUITING	Reducing Missed Appointments
NCT07377032	PHASE3	RECRUITING	TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders
NCT02909959	PHASE2	COMPLETED	Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder
NCT06081348	PHASE2	RECRUITING	Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
NCT06352372	PHASE2	COMPLETED	Safety and Efficacy of tPBM for Epileptiform Activity in Autism
NCT00503191	PHASE1	COMPLETED	NeuroModulation Technique Treatment of Autism
NCT04475848	PHASE1	COMPLETED	A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 in Healthy Participants
NCT06300398	PHASE1	COMPLETED	IAMA-6 Oral Dose Study in Healthy Adults
NCT01783041	PHASE2/PHASE3	COMPLETED	Effect of Early L-Carnitine Supplementation on Neurodevelopmental Outcomes in Very Preterm Infants
NCT05767385	PHASE2/PHASE3	RECRUITING	Fetal Cerebrovascular Autoregulation in Congenital Heart Disease and Association With Neonatal Neurobehavior
NCT05675098	EARLY_PHASE1	NOT_YET_RECRUITING	Central Nervous System Stimulants and Physical Function in Children With Cerebral Palsy
NCT00783783	Not specified	COMPLETED	CYP2D6 Pharmacogenetics in Risperidone-Treated Children
NCT01778504	Not specified	RECRUITING	Studying Childhood-onset Behavioral, Psychiatric, and Developmental Disorders
NCT01850784	Not specified	UNKNOWN	High Energy Formula Feeding in Infants With Congenital Heart Disease
NCT01922791	Not specified	COMPLETED	Nutrition and Pregnancy Intervention Study
NCT01942525	Not specified	UNKNOWN	Influence of Intrauterine Growth Restriction on Amplitude-integrated EEG in Preterm Infants
NCT02003170	Not specified	COMPLETED	Etiology and Early Diagnosis of Neurodevelopmental Disorders
NCT02118649	Not specified	ACTIVE_NOT_RECRUITING	Enhancing Behavior and Brain Response to Visual Targets Using a Computer Game
NCT02557191	Not specified	TERMINATED	Biomarkers, Neurodevelopment and Preterm Infants
NCT02690675	Not specified	COMPLETED	Iron Supplement Effect on Child Development
NCT02694003	Not specified	COMPLETED	Better Nights, Better Days for Children With Neurodevelopment Disorders
NCT02792894	Not specified	COMPLETED	Family Networks (FaNs) for Children With Developmental Disorders and Delays
NCT02871674	Not specified	UNKNOWN	Good Night Project: Behavioural Sleep Interventions for Children With ADHD: A Randomised Controlled Trial
NCT02887157	Not specified	COMPLETED	Analyzing Retinal Microanatomy in ROP
NCT02898298	Not specified	COMPLETED	Positive Emotion Regulation Training in Children, Adolescents and Young Adults With and Without Developmental Disorder
NCT02912780	Not specified	UNKNOWN	Introduction of Microsystems in a Level 3 Neonatal Intensive Care Unit
NCT03023293	Not specified	COMPLETED	n-3 PUFAs, Irisin and Maternal Glucose Metabolism From Pregnancy to Postpartum
NCT03023644	Not specified	COMPLETED	Improving Neurodevelopmental Outcomes in Children With Congenital Heart Disease: An Intervention Study
NCT03032991	Not specified	UNKNOWN	Early Biomarkers of Neurodevelopment in Offspring of Diabetic Mothers
NCT03088189	Not specified	TERMINATED	Effect of Parental Peri-conceptional Vitamin B12 Supplementation on Infant Neurocognitive Development in Offspring
NCT03096028	Not specified	COMPLETED	Developmental Origins of Mental Health Disorders
NCT03148782	Not specified	COMPLETED	Brain Plasticity Underlying Acquisition of New Organizational Skills in Children-R61 Phase
NCT03172104	Not specified	COMPLETED	Neurobehavioural Development of Infants Born <30 Weeks Gestational Age Between Birth and Five Years of Age
NCT03222375	Not specified	RECRUITING	SQUED™ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism
NCT03229928	Not specified	COMPLETED	Clinical Testing of a Real-Time Behavior Measurement Tool: Measuring Outcomes for CHAnge
NCT03232489	Not specified	UNKNOWN	Study for the Evaluation of the Feasibility of Applying Advanced MRI Scanning in Pediatric Clinical Practice